Literature DB >> 3113524

Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer.

K Jauhiainen, O Alfthan.   

Abstract

Both Mitomycin C (MMC) and doxorubicin (Adriamycin) (ADM) prevent the recurrence of superficial papillary (Ta-T1) urinary bladder cancers and also reduce the rate of progression. MMC appears to be more effective than ADM in buffered instillations. The number of recurrent tumours (RI/m) and the number of recurrence times (RR) before prophylactic instillation were of significant prognostic importance but the prognostic value of the grade was questionable. The buffer solution, together with methyl prednisolone, reduced the incidence of chemical cystitis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3113524     DOI: 10.1111/j.1464-410x.1987.tb09134.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  4 in total

Review 1.  Current concepts in the role of intravesical instillations in the therapy and prophylaxis of superficial transitional-cell cancer of the bladder. The Finnbladder Research Group.

Authors:  O Alfthan; K Jauhiainen; E Kaasinen; T Liukkonen
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

2.  Intravesical treatment of bladder cancer with recombinant human interferon-beta. Intravesical GKT-beta Chemotherapy Research Group.

Authors:  T Niijima
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  The efficacy of intravesical BCG in the treatment of patients with high risk superficial bladder cancer.

Authors:  L Samodai; L Kiss; Z Kolozsy; L Mohácsi
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

4.  Prophylactic chemotherapy for primary and recurrent superficial bladder cancer: preliminary results. The Hokkaido University Bladder Cancer Collaborating Group.

Authors:  M Togashi; N Shinohara; K Toyota; T Koyanagi; A Maru; J Fujieda; K Kawakura; T Nishida; N Ohashi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.